Lantern Pharma Granted Fast-Track Designation for Glioblastoma Drug
Lantern Pharma Inc., an AI-driven cancer therapy developer, announced FDA Fast Track Designation for its investigational drug, LP-184, targeting glioblastoma. Currently, in Phase 1A trials to assess safety across various solid tumors, including glioblastoma, LP-184 was optimized through Lantern's AI platform, RADR®, which helps identify mechanisms to tackle difficult cancers and supports precision targeting in patient populations.
Lantern Pharma Granted Fast-Track Designation for Glioblastoma Drug